Clinical Trial Update: The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating how dapagliflozin affects HDL particle subtypes and reverse cholesterol transport in patients with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Padova | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED